NRG1 and non-small cell lung carcinoma: The multi-kinase inhibitor cabozantinib is in a phase II clinical trial for ROS1 and NTRK-altered NSCLC, and seribantumab, a monoclonal antibody, is being tested for NRG1-altered advanced NSCLC [27,33].